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Abstract 
Purpose: The EuroQol five-dimension questionnaire (EQ-5D) is the most commonly used 
instrument to obtain utility values for cost-effectiveness analyses of treatments for Crohn’s 
disease (CD). We aimed to compare the measurement properties of the two adult versions of 
EQ-5D (EQ-5D-3L and EQ-5D-5L) in patients with CD. 
Methods: Between 2016 and 2017, a multicentre cross-sectional survey was carried out. 
Consecutive outpatients with CD completed the 3L, 5L and EQ visual analogue scale (VAS). 
Disease severity was graded by the Crohn's Disease Activity Index (CDAI) and Perianal 
Disease Activity Index (PDAI). The 3L and 5L were compared in terms of feasibility, 
agreement, ceiling effect, redistribution properties, discriminatory power, convergent and 
known-groups validity.  
Results: 206 patients (54.9% male, mean age 35±11y) participated in the survey. For 3L, 25 
unique health states were observed versus 59 for the 5L. The overall ceiling effect decreased 
from 29.6% (3L) to 25.5% (5L). Absolute discriminatory power improved (mean Shannon 
index 0.84 vs. 1.18). The 3L correlated stronger with EQ VAS and CDAI scores, whereas the 
5L with PDAI. The 5L demonstrated a better known-groups validity on the basis of age, 
perianal fistulas, extraintestinal manifestations and disability.  
Conclusions: This is the first study to report the impact of CD on quality of life using  the EQ-
5D-5L questionnaire. The 5L seems to perform better than 3L in terms of feasibility, ceiling 
effect, discriminatory power and known-groups validity. Understanding the differences in 
psychometrics between the 3L and 5L is essential as they have substantial implications for 
financial decision-making about CD treatments.  
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Introduction 
Crohn’s disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract affecting 
over 2 million people in Europe [1,2]. Patients with CD may present a broad spectrum of 
symptoms including diarrhea, abdominal pain, rectal bleeding, fever, fatigue and mental 
problems [3]. Over time complications such as strictures, fistulas, abscesses and extraintestinal 
manifestations (e.g. arthritis, uveitis/iritis or skin inflammation) may develop in up to 50% of 
CD patients [3,4]. The chronic relapsing nature of the disease has a detrimental impact on 
patients’ health-related quality of life (HRQoL) [5]  
In the past 15 years, the introduction of biological drugs has revolutionised the treatment of 
CD. Biologics are costly alternatives compared to conventional treatments; thus, evidence on 
their cost-effectiveness is required for reimbursement decisions [6-9]. In many countries 
including the US, Canada, Australia, the UK, France, Belgium, the Netherlands, Spain, 
Hungary and Poland, the EuroQol five-dimension questionnaire (EQ-5D) is among the 
preferred tools to measure HRQoL for cost-effectiveness analyses by national health 
technology assessment agencies [10-17]. So far, the EQ-5D has been used in a number of cost-
effectiveness analyses of biologics and biosimilars to value the health gains from treatment [18-
22]. According to a recent systematic literature review, the EQ-5D is the most frequently 
applied generic preference-based measure of HRQoL in CD patients [23]. 
Two versions of the EQ-5D were developed for use on adult populations, the EQ-5D-3L 
(hereafter 3L) in 1990 and the EQ-5D-5L (hereafter 5L) in 2011 [24]. Nearly 20 studies in CD, 
involving observational studies and randomised controlled trials [23], applied the 3L version, 
for which validity and reliability had been demonstrated in this patient population [25,26]. The 
5L, an expanded version of the 3L, was introduced by the EuroQol Group with the intention of 
reducing ceiling effects and improving discriminatory power [27,28]. A number of studies have 
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confirmed the improved psychometric properties of the 5L in both general population and 
patient samples, including cancer, chronic hepatic diseases, diabetes, osteoarthritis, psoriasis 
and stroke [29]. No studies have reported on HRQoL in patients with CD as assessed by the 
5L, and only two published clinical trial protocols, planning to use the 5L questionnaire in  CD 
patients, are present  [30,31]. Nevertheless, as of the time this manuscript was written, results 
are not yet available. 
Given the growing number of biological and biosimilar treatments available for CD [7,9,32] an 
increased use of the 5L is expected in the years to come. Understanding the differences in 
psychometrics between the 3L and 5L is essential as they might have substantial implications 
for clinical and financial decision-making. Therefore, the objective of the current study is to 
assess the validity of the 5L and to compare its measurement properties to that of the 3L in the 
same set of patients with CD. We aim to test the following psychometric properties: feasibility, 
agreement, ceiling effect, redistribution properties, discriminatory power, convergent and 
known-groups validity. 
 
Materials and methods 
Study design and patient population 
Between October 2016 and September 2017, a multicentre, cross-sectional survey was 
conducted at three academic gastroenterology departments and an inflammatory bowel diseases 
centre in three large cities (Budapest, Debrecen and Szeged) in Hungary. Consecutive 
outpatients over 18 years of age diagnosed with CD were enrolled. The survey comprised of a 
paper-based questionnaire, first part of which was completed by the patients, and the second by 
their gastroenterologist. Patients were asked about socio-demographic characteristics, general 
health status and HRQoL. Gastroenterologists provided data about medical history, clinical 
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characteristics, disease severity and treatments. Permission for conducting the study was 
granted by the National Scientific and Ethical Committee of Hungary (Reference No. 49548-
4/2016/EKU). All patients signed an informed consent form before collection of any data. 
 
Measures 
All patients completed a set of questionnaires including the validated Hungarian versions of the 
5L, 3L, EQ visual analogue scale (VAS), Patients' Global Assessment VAS (PGA VAS), 
Patients' Global Assessment on fistula symptoms VAS, a pain VAS and a worst pain 
experienced in the past 3 months VAS. 
 
EQ-5D-3L and EQ-5D-5L questionnaires 
The EQ-5D is a generic, self-reported measure of current health that consists of a five-item 
descriptive system and a visual analogue scale (EQ VAS) [33,34]. The descriptive system has 
two versions, namely the 3L and 5L, both involving five health dimensions (mobility, self-care, 
usual activities, pain/discomfort and anxiety/depression). The EQ VAS records the patient’s 
current self-rated health on a 20-cm-long vertical scale ranging from 0 (‘The worst imaginable 
health state’) to 100 (‘The best imaginable health state’).  
In each dimension of the 3L version, subjects may choose from three response levels (no 
problems=1, some/moderate problems=2, extreme problems/unable to/confined to bed=3) 
allowing to define a total of 35 (=243) unique health states. In the 5L the response levels are 
expanded to five categories in each dimension (no problems=1, slight problems=2, moderate 
problems=3, severe problems=4 and unable to/extreme problems=5) providing 55 (=3125) 
distinct health states. It is worthy of note that the wording of levels is standardised in the 5L 
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[27]. The intermediate level is consistently ‘moderate’ in all dimensions of the 5L, and the worst 
level of mobility has been changed from ‘confined to bed’ (3L) to ‘unable to walk about’ (5L). 
In the Hungarian EQ-5D, another amendment was made when switching from the 3L to the 5L 
in order to be harmonized with other language variants, the label of ‘anxiety/depression’ was 
reworded, ‘szorongás/lehangoltság’(=anxiety/feeling blue) in the 3L was replaced by 
‘szorongás/depresszió’ (=anxiety/depression) in the 5L [35].In accordance with earlier studies, 
the 5L preceded the 3L in the questionnaire, in order to prevent the underuse of level 2 and 4 
on the 5L [36]. To avoid duplication in data collection, the EQ VAS was completed only once 
(right after the 5L descriptive system). 
The EQ-5D responses may be converted into an EQ-5D index score (utility value) reflecting 
social preferences for each specific health state [37]. In absence of national value sets in 
Hungary, the 3L value set for the UK by Dolan [38] and the 5L value set for England by Devlin 
et al.[39] were applied in this study to derive EQ-5D index scores. The major reason for this 
choice was that the UK/English value set is recommended to use in countries with no national 
tariffs [14]. In these value sets, the ‘11111’ descriptive health state equals to 1 (full health), 
whilst the two worst health states, the ‘33333’ in the 3L and the ‘55555’ in the 5L correspond 
to -0.594 and -0.285, respectively [38,39]. 
 
Crohn's Disease Activity Index (CDAI) 
The CDAI is a widely used outcome measure to evaluate disease activity in patients with CD 
[40]. It is primarily based on an eight-item list of clinical symptoms or laboratory findings in 
the past seven days, including the number of liquid or soft stools per day, abdominal pain, 
general well-being, presence of extraintestinal manifestations, treatment with antidiarrheal 
drugs, presence of an abdominal mass, haematocrit and body weight. Total score is calculated 
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by physicians as a sum of products of the items multiplied by weighting factors. CDAI total 
scores range from 0 to 600, where a higher score represents worse disease activity. Established 
cut-offs are as follows: <150 non-active disease or remission, 150-219 mildly active, 220-449 
moderately active and 450-600 severely active disease [41]. 
 
Perianal disease Activity Index (PDAI) 
PDAI is a validated scoring system to evaluate severity of perianal fistulising CD [42]. The 
PDAI includes five items (i.e. discharge, pain/restriction of activities, restriction of sexual 
activity, type of perianal disease and degree of induration), each of them is rated on a five-point 
scale ranging from no symptoms (=0) to severe symptoms (=4). Total PDAI score varies 
between 0 and 20, where a higher score indicates a more severe disease. PDAI of ≤4 identifies 
inactive disease requiring no therapy, whereas a PDAI of >4 suggests active disease [43]. 
 
Visual analogue scales 
To assess disease severity and fistula-related disease severity the Patient's Global Assessment 
(PGA) VAS, and Patients' Global Assessment on fistula symptoms VAS (0-100) were 
administered, both providing a range of scores from 0-100, where 0 indicated ‘not severe at all’ 
and 100 represented ‘very severe’. 
The current and worst CD-related pain intensities experienced by the patients in the past three 
months were recorded on a horizontal VAS with the endpoints of ‘no pain at all’ (=0) and ‘pain 
as bad as it could be’ (=100) [44].   
 
Statistical analyses 
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Data analysis was performed according to the criteria proposed in previous studies attempting 
to compare the measurement properties of the 3L and 5L in other populations [36,45-47].  
 
Feasibility  
We computed the proportion of patients not answering to a few (i.e. partially incomplete 
questionnaire) or all dimensions (i.e. incomplete questionnaire) of the EQ-5D. Feasibility was 
compared by calculating the percentage of missing values for all dimensions of the 3L and 5L.  
 
Agreement 
The agreements among the 3L and 5L EQ-5D index scores were examined using an intraclass 
correlation coefficient (ICC) and a Bland-Altman plot. A two-way random model with absolute 
agreement was applied to obtain an ICC value [48]. Agreement is considered poor for ICC 
values between 0 and 0.39, fair between 0.40 and 0.59, good between 0.60 and 0.74 and 
excellent between 0.75 and 1 [49]. The Bland-Altman plot shows the differences between 3L 
and 5L index scores (y-axis) and the means of these scores (x-axis) [50].  
 
Ceiling effect 
The proportion of patients reporting ‘no problems’ was calculated for each dimension of the 
descriptive system. We also computed the proportion of patients reporting ‘no problems’ in all 
five dimensions (11111 vector). We assumed that the ceiling effect would be lower for 5L 
compared with 3L suggesting a better discriminatory power of the 5L version. We estimated 
the absolute and relative reduction when going from 3L to 5L. The relative reduction (%) was 
computed as: 
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𝑐𝑒𝑖𝑙𝑖𝑛𝑔3𝐿 − 𝑐𝑒𝑖𝑙𝑖𝑛𝑔5𝐿
𝑐𝑒𝑖𝑙𝑖𝑛𝑔3𝐿
× 100 
Redistribution properties 
Redistribution properties were defined as proportions of 3L-5L response pairs in each 
dimension from the same patient [36]. We computed the percentage of consistent and 
inconsistent 3L-5L response pairs as well as the average size of inconsistency for each 
dimension. A response pair was considered inconsistent when a 3L response was two or more 
levels away from the 5L response; for example, in any dimension, a patient marks level 1 in the 
3L but level 3 in the 5L version. The mean size of inconsistency was calculated according to 
the following weights: 0 = responses differ by a maximum of one level (i.e. consistent response 
pair), 1 = responses differ by two levels, 2 = responses differ by three levels and 3 = responses 
differ by four levels [36].  
 
Discriminatory power 
One may hypothesise that the 5L with its two extra levels has a better discriminatory potential 
(informativity). However, the discriminatory power improves only if the new levels are 
effectively used. To test this, we calculated Shannon and Shannon Evenness indices for each 
dimension separately [51,52]. The Shannon index (H’) was defined as: 
𝐻′ = −∑𝑝𝑖𝑙𝑜𝑔2𝑝𝑖
𝐿
𝑖=1
 
 
where L denotes the number of levels in a dimension of the descriptive system, and pi is the 
proportion of observations in the ith level (i = 1, …, L). The optimal amount of information is 
captured when the responses are evenly distributed across levels (i.e. rectangular distribution). 
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In this case, H’ reaches its maximum value at log2L which equates to 1.58 for the 3L and 2.32 
for the 5L. The higher the H’, the more information is obtained and the better the discriminatory 
power is. 
The Shannon Evenness index (J’), combines the evenness (rectangularity) of a distribution and 
the number of levels used. J’ was calculated by using the following formula: 
𝐽′ =
𝐻′
𝐻′𝑚𝑎𝑥
 , where H’max =log2L. 
 
A higher J’ of the 5L expresses a better discriminatory power, while a lower J’ indicates a loss 
in potential of the 5-level dimensions compared to the 3L. 
 
Convergent and known-groups validity 
Convergent validity of the EQ-5D dimensions and index scores with EQ VAS, CDAI, PDAI, 
PGA VAS, PGA fistula VAS, pain VAS and worst pain VAS was tested by Spearman’s rank 
order correlations. The correlation coefficient (rs) was interpreted as follows: very weak 
correlation rs<0.2, weak correlation 0.20≤rs<0.4, moderate correlation 0.4≤rs<0.6 and strong 
correlation 0.6≤rs≤1 [53]. Known-groups validity was evaluated for age groups and all relevant 
clinical characteristics. We hypothesised that patients with older age, more severe disease, 
perianal fistulas, extraintestinal manifestations, disability or permanent stoma have lower EQ-
5D index scores. Wilcoxon signed-rank test was applied to test the difference between 3L and 
5L index scores across these groups, whereas Mann-Whitney U or Kruskal Wallis H tests were 
used to assess between-group differences in the 3L and 5L. All the statistics were two-sided, 
and p<0.05 was considered statistically significant. Data were analysed by using IBM SPSS 
22.0. Armonk, NY: IBM Corp (2013).  
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Results 
Patient characteristics 
A total of 206 eligible patients with CD completed the survey (Table 1). The majority of the 
sample were men (54.9%), and the mean age was 34.7 years (range 18-70). Mean disease 
duration was 10.5 (SD 6.3) years. At the time of the survey, 41% had a fistulising disease, and 
approximately one-third of these had active perianal fistula(s). Extraintestinal manifestations 
were present in 27.7% of cases. Among the patients, 66% received biological therapy: 
infliximab (46.6%), adalimumab (17.5%) and vedolizumab (1.9%). There were 10 (4.9%) 
patients in the sample with a permanent stoma. According to CDAI scores, three-quarter of the 
patients were in symptomatic remission. Mean disease severity, global assessment and pain 
scale scores are described in Table 1. 
 
Feasibility 
No questionnaires were returned blank, but there were three and two partially incomplete 3L 
and 5L descriptive systems, respectively. In all but one cases, the number of missing answers 
per patient was only one. There were no missing values on the EQ VAS.  
 
 
Agreement 
Overall, a good agreement was observed between the 3L and 5L (ICC=0.707, 95% CI 0.363-
0.844; p<0.0001). Mean 3L index scores were significantly lower compared to the 5L 
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(0.80±0.20 and 0.87±0.12; p<0.0001). The Bland-Altman plot confirmed the good level of 
agreement between the two measures (Fig.2). Differences between index scores tended to 
increase at lower mean values. 
 
Distribution and ceiling effect 
For 3L, 25 unique health states were observed versus 59 for the 5L. Distribution of EQ-5D 
index scores is presented in Fig.1. There were two negative values in the 3L and none in the 
5L.  
Patients reported the least problems with self-care (rate of ‘1’ responses: 94.7% in 3L and 
94.1% in 5L), whereas the most problems occurred with pain/discomfort (rate of ‘1’ responses: 
43.7% in 3L and 38.3% in 5L) (Table 2). The other three dimensions varied in between. The 
proportion of ‘11111’ profiles (index score=1) decreased from 29.6% on the 3L to 25.5% on 
the 5L indicating an overall absolute ceiling effect reduction of 4.1% and a relative ceiling 
effect reduction of 13.3%. Absolute and relative ceiling effect reductions were the highest for 
the mobility and the lowest for the anxiety/depression item. There were a total of nine (4.4%) 
‘100’ responses on the EQ VAS. 
 
Redistribution properties and inconsistencies 
Cross-tabulations of responses to the 3L and 5L showed that responses covered all levels for 
both EQ-5D versions (Table 3). No 3L responses were more than two levels away from their 
5L response pairs. Only 24 (2.3%) response pairs did not meet the criteria for consistency, and 
these were given by 21 (10.2%) patients. The average size of overall inconsistency was very 
low (1.0). The lowest rate of inconsistent responses was observed in mobility and self-care 
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dimensions (0.5%), whereas the highest in the pain/discomfort and anxiety/depression 
dimensions (3.9%) (Table 4).  
 
Discriminatory power 
When moving from 3L to 5L, absolute discriminatory power (Shannon index, H’) improved 
across all dimensions (3L 0.30 to 1.06 vs. 5L 0.37 to 1.65) indicating that the extra levels were 
effectively used (Table 4). The average H’ value improved from 0.84 for the 3L to 1.18 for the 
5L. Relative discriminatory power (Shannon Evenness index, J’) marginally increased for the 
dimension of pain/discomfort, while declined for the other four dimensions. The average values 
of J’ for the 3L and 5L were 0.53 and 0.51, respectively. 
 
Convergent validity 
With respect to index scores, the 3L and 5L produced a strong and a moderate-to-strong 
correlation with EQ VAS, respectively (Table 5). The 3L indicated better correlations with EQ 
VAS for all dimensions except for anxiety/depression. For individual dimensions, the minimum 
value of correlation coefficient was found for self-care (-0.096) and the maximum for usual 
activities (-0.568). In contrast, in 5L, correlation coefficients with EQ VAS ranged from -0.091 
(self-care) to -0.525 (pain/discomfort).  
For both EQ-5D versions, very weak correlations were observed with CDAI scores across all 
dimensions, with a better overall performance of the 3L. As opposed to these, in all but one 
dimensions the 5L provided stronger correlations with PDAI and in all dimensions with PGA 
VAS, PGA fistula VAS and current pain VAS. Considering the worst pain experienced in the 
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past 3 months, the 5L exhibited a better convergent validity for the usual activities, 
pain/discomfort and anxiety/depression domains. 
 
Known-groups validity 
The mean and median of 5L were higher than the corresponding mean and median of 3L in all 
subgroups of patients (Table 6). Subjects with extraintestinal manifestations and those who 
were disabled due to CD tended to have significantly lower index scores, as measured by both 
instruments (p<0.05). The 5L was able to better distinguish between groups based on age, 
perianal fistulas and permanent stoma.  
Discussion 
This study aimed to compare the psychometric properties of two versions of the EQ-5D 
questionnaire in a sample of patients diagnosed with CD. A good agreement was found between 
the two instruments, albeit, one might expect higher ICC value than 0.707, given the same 
underlying construct. In comparison, ICC values of 0.759 and 0.94 were reported in a young 
adult general population in Portugal and among patients with psoriasis in Greece, respectively 
[56,57]. In accordance with earlier studies, the Bland-Altman plot confirmed a strong 
agreement between the two measures [56,57]. 
One of the primary aims in introducing the 5L was to reduce the number of patients with 11111 
(full health) responses. As expected, the expansion of the response levels in the EQ-5D 
descriptive system decreased ceiling effect, especially in the pain/discomfort and usual 
activities dimensions. The proportion of CD patients reporting no problems declined by 4.1%. 
This is similar to the magnitude of reduction in ceiling effect observed in chronic hepatic 
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diseases (2.9%) and psoriasis (4.2%) [54,35]. Nevertheless, it is considerably smaller compared 
to those found in patients with hepatitis B (16.7%) and diabetes (20.0%) [55,58]. 
According to a recent systematic review by Buchholz et al. 14 previous studies involving 
various patient or general population samples have analysed the informativity of the 5L and 3L 
by computing Shannon indices [29]. In all of these studies, the H’ was higher for the 5L than 
for the 3L indicating that more information is captured by the 5L. The J’ was, however, higher 
for the 5L in nine studies and slightly lower in five studies – similarly to our study in patients 
with CD. A possible explanation for this is the very limited use of levels 4 and 5 in the 5L and 
level 3 in the 3L because of the high number of patients in remission or with mildly active 
disease.  
With regard to convergent and known-groups validity with the reference measures, some 
differences were identified between the 3L and 5L. In our study the 5L performed better in 24 
out of the 35 correlation coefficients (69%). This figure is in accordance with previous studies 
in which some disease-specific outcome measures correlated better with the 5L, while others 
with the 3L. For example, the 5L demonstrated slightly better convergence validity with 
Psoriasis Area and Severity Index but not with the Dermatology Life Quality Index (DLQI) in 
psoriasis [35], with the Eastern Cancer Oncology Group (ECOG) and the European 
Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 
(EORTC QLQ 30) scales in cancer [60], and none of Barthel Index and modified Rankin scale 
in stroke [61]. We observed that the 5L exhibited weaker correlations with EQ VAS in CD (4/5 
dimensions). For the sake of comparison, the 5L produced higher correlation coefficients in 
patients with hepatitis B (4/5 dimensions) [55], cancer (5/5 dimensions) [60] and total hip 
arthroplasty (4/5 dimensions) [62], but not in psoriasis (1/5 dimension) [35]. The underlying 
reasons for such differences may be attributed to the variations in patient populations including 
the characteristics and severity of the disease, and the extent of use of response levels on the 
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EQ-5D descriptive system by patients with different conditions. In terms of known-groups 
validity, the 5L was able to more precisely detect differences between subgroups of patients 
based on age and important clinical characteristics. Both versions detected significantly lower 
EQ-5D index scores in patients with extraintestinal manifestations. As mentioned previously, 
arthritis/arthralgia has represented the majority of these extraintestinal symptoms which can be 
relatively easily captured by the mobility dimension of the EQ-5D. 
As opposed to patient-reported scales, both systems showed weak or very weak correlations 
with measures of disease severity assessed by physicians (CDAI and PDAI). Previous studies 
found moderate or strong correlations between the 3L index and CDAI scores [25,26,63]. This 
difference may be attributable to variations in the composition of patient populations examined 
in these studies (e.g. disease characteristics and severity, type of treatment). Other sources of 
difference lie in the time horizon of the EQ-5D and CDAI (today vs. previous seven days), the 
interobserver variability [64] and the accuracy of CDAI score calculation. The CDAI is based 
on symptoms, signs and blood test results, and studies reported that a poor correlation exists 
between CDAI scores and endoscopic indices [65-67]. Consequently, the weak correlation 
between the EQ-5D and CDAI does not imply that the EQ-5D can poorly distinguish severity 
groups of CD patients. 
Large systematic differences between 3L and 5L index scores can be observed, which are 
resulting from how individuals respond to the changed descriptive system and from the 
differences between the 3L (UK) and the 5L (English) value sets [68,69]. As shown in a recent 
study by Hernández Alava et al. the 3L and 5L utilities are not interchangeable, as they can 
produce substantially different cost-effectiveness results [70]. To put this into context, 
biological treatments for CD mostly improve HRQoL, rather than reducing mortality; thus, a 
drug would be deemed as more cost-effective if the 3L had been used in place of the 5L. 
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Examining how the differences between the 3L and 5L results impact existing cost-
effectiveness analyses of biologics and biosimilars might be an important future challenge. 
The multicentre design that involved four clinics from three different cities, the heterogeneous 
patient population and the large number of outcome measures utilised in the survey can be 
considered as strengths of the study. This is the first study in the literature to compare the 
measurement properties of the 3L and 5L in CD patients; additionally, the first to report the 
impact of CD on HRQoL using the 5L version of the questionnaire.  
The greatest limitation of the study is that patients in severe health states were underrepresented 
in the sample, mostly because two-third of our patients were treated with biologics. 
Nonetheless, the patient population was heterogeneous in terms of clinical manifestation of the 
disease, which was excellent for the purpose of study. A further limitation of our study is the 
moderate sample size. Finally, we did not test some other important psychometric properties 
such as sensitivity and test-retest reliability, which could not be investigated here because of 
the cross-sectional nature of the survey. 
In conclusion, in patients with CD, the 5L performed well in terms of feasibility, agreement, 
ceiling effect, consistency, absolute discriminatory power and known-groups validity. 
Nonetheless, it somewhat lagged behind the 3L in convergent validity with EQ VAS and CDAI. 
Further longitudinal studies are needed that compare the responsiveness and reliability of the 
two descriptive systems. Another future research direction is to examine the relationship of EQ-
5D index scores and endoscopic markers that might better reflect disease severity than CDAI 
scores.  
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Tables 
Table 1 Patient characteristics 
  Mean (SD) or n (%) 
Gender   
Female 93 (45.1%) 
Male 113 (54.9%) 
Age (years) 34.7 (10.5) 
Employment status§   
Student 25 (12.1%) 
Full-time employed 110 (53.4%) 
Part-time employed 30 (14.6%) 
Unemployed 11 (5.3%) 
Retired 3 (1.5%) 
Disabled due to Crohn’s disease 49 (23.8%) 
Other 15 (7.3%) 
Disease duration (years) (missing n=1) 10.5 (6.3) 
Fistulas§ 84 (40.8%) 
Perianal 84 (40.8%) 
Other 2 (1.0%) 
Extraintestinal manifestations§ 57 (27.7%) 
Arthritis/arthralgia 44 (21.4%) 
Iritis/uveitis  8 (3.9%) 
Skin symptoms 8 (3.9%) 
Other† 3 (1.5%) 
Permanent stoma 10 (4.9%) 
Treatments  
None 3 (1.5%) 
Systemic non-biological 67 (32.5%) 
Biological 136 (66.0%) 
Outcome measures  
Disease severity  
CDAI (0-600) (missing n=2) 110.49 (76.97) 
PDAI (0-20) (missing n=1) 3.68 (2.29) 
PGA VAS (0-100) (missing n=2) 50.11 (23.87) 
PGA fistula VAS (0-100) (missing n=11) 44.87 (25.72) 
Pain  
Pain VAS (0-100) 24.65 (23.90) 
Worst pain experienced in the past 3 months VAS (0-100) 41.95 (31.36) 
Health-related quality of life*  
EQ-5D-5L (-0.285-1) (missing n=2) 0.87 (0.12) 
EQ-5D-3L (-0.594-1) (missing n=3) 0.80 (0.17) 
EQ VAS (0-100) 72.74 (19.67) 
§ Combinations occurred. † Vasculitis, aphtous stomatitis and primary sclerosing cholangitis were present in one 
patient each. *We found two negative values for the EQ-5D-3L and no negative values for the EQ-5D-5L. 
CDAI = Crohn's Disease Activity Index; PDAI = Perianal disease Activity Index; PGA VAS = Patients' Global 
Assessment visual analogue scale; PGA fistula VAS = Patients' Global Assessment on fistula symptoms visual 
analogue scale; VAS = visual analogue scale. 
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Higher scores represent worse health state for all outcome measures with the exception of EQ-5D-3L, EQ-5D- 
5L and EQ VAS. 
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Table 2 Ceiling effects 
Dimension 3L (n, %) 5L (n, %) 
Ceiling effect reduction 
Absolute Relative (%) 
Mobility 168 (81.6%) 161 (78.5%) 3.02% 4.17% 
Self-care 195 (94.7%) 192 (94.1%) 0.54% 1.54% 
Usual activities 129 (62.9%) 119 (57.8%) 5.16% 7.75% 
Pain/discomfort 90 (43.7%) 79 (38.3%) 5.34% 12.22% 
Anxiety/depression 118 (57.8%) 118 (57.3%) 0.56% 0.00% 
Overall (11111) 60 (29.6%) 52 (25.5%) 3.60% 13.33% 
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Table 3 Redistribution properties from 3L to 5L: cross tabulation of dimension scores 
(n, %)  
 3L Dimension 
5L 
1 2 3 4 5 
1 
Mobility 160 (95.2%) 8 (4.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Self-care 191 (98.5%) 3 (1.5%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Usual activities 114 (88.4%) 14 (10.9%) 1 (0.7%) 0 (0.0%) 0 (0.0%) 
Pain/discomfort 74 (82.2%) 13 (14.4%) 3 (3.3%) 0 (0.0%) 0 (0.0%) 
Anxiety/depression 111 (94.1%) 5 (4.2%) 2 (1.7%) 0 (0.0%) 0 (0.0%) 
2 
Mobility 1 (2.7%) 26 (70.3%) 9 (24.3%) 1 (2.7%) 0 (0.0%) 
Self-care 1 (10.0%) 7 (70.0%) 1 (10.0%) 1 (10.0%) 0 (0.0%) 
Usual activities 5 (7.0%) 35 (48.6%) 30 (41.7%) 2 (2.7%) 0 (0.0%) 
Pain/discomfort 5 (4.4%) 70 (61.4%) 37 (32.5%) 2 (1.8%) 0 (0.0%) 
Anxiety/depression 6 (7.1%) 58 (69.1%) 20 (23.8%) 0 (0.0%) 0 (0.0%) 
3 
Mobility 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Self-care 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Usual activities 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (50.0%) 2 (50.0%) 
Pain/discomfort 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (50.0%) 1 (50.0%) 
Anxiety/depression 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (100.0%) 0 (0.0%) 
There were altogether 24 (2.3%) inconsistent response pairs provided by 21 (10.2%) patients. The size of 
inconsistency is represented in grayscale with more inconsistency in darker fields [47]. 
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Table 4 Inconsistency between the 3L and 5L versions and Shannon (H') and Shannon Evenness index (J') 
Dimension 
Patients 
(n) 
Inconsistency Shannon indices, 3L Shannon indices, 5L 
Inconsistent 
response pairs (n, 
%) 
Average size of 
inconsistencies 
n H' J' n H' J' 
Mobility 205 1 (0.5%) 1.00 206 0.73 0.46 205 0.94 0.41 
Self-care 204 1 (0.5%) 1.00 206 0.30 0.19 204 0.37 0.16 
Usual activities 205 6 (2.9%) 1.00 205 1.06 0.67 206 1.54 0.66 
Pain/discomfort 206 8 (3.9%) 1.00 206 1.06 0.67 206 1.65 0.71 
Anxiety/depression 204 8 (3.9%) 1.00 204 1.05 0.66 206 1.40 0.60 
Total/mean - 24 (2.3%) 1.00 - 0.84 0.53 - 1.18 0.51 
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Table 5 Convergent validity: Spearman's correlation coefficients 
 
Dimension 
EQ VAS CDAI PDAI 
Patients' Global 
Assessment VAS 
(0-100) 
Patients' 
Global 
Assessment on 
fistula 
symptoms 
VAS (0-100) 
Pain VAS (0-100) 
Worst pain 
experienced in the 
past 3 months VAS 
(0-100) 
3L 5L 3L 5L 3L 5L 3L 5L 3L 5L 3L 5L 3L 5L 
Mobility -0.297* -0.285* -0.034 -0.028 0.044 0.132 0.192* 0.257* -0.084 0.098 0.181* 0.193* 0.265* 0.262* 
Self-care -0.096 -0.091 0.047 0.055 0.146 0.165 0.113 0.160* 0.031 0.153 0.057 0.067 0.167* 0.158* 
Usual 
activities 
-0.568* -0.523* 0.129 0.089 0.148 0.169 0.423* 0.449* 0.110 0.187 0.434* 0.442* 0.386* 0.454* 
Pain/discomfo
rt 
-0.547* -0.525* 0.188* 0.182* 0.226* 0.285* 0.401* 0.474* 0.116 
0.308
* 
0.608* 0.652* 0.484* 0.584* 
Anxiety/depre
ssion 
-0.338* -0.339* 0.126 0.153* 0.062 0.044 0.184* 0.248* 0.149 
0.245
* 
0.201* 0.235* 0.227* 0.304* 
EQ-5D index 
score 
0.606* 0.575* -0.175* -0.144* -0.208 -0.232* -0.417* -0.494* -0.096 
0.281
* 
-0.561 -0.539* -0.499* -0.570* 
* p<0.05 for all correlation coefficients. 
Bold and italic values indicate a lower correlation coefficient of the 5L compared to the 3L. 
CDAI = Crohn's Disease Activity Index; PDAI = Perianal disease Activity Index; PGA VAS = Patients' Global Assessment visual analogue scale; PGA fistula VAS = 
Patients' Global Assessment on fistula symptoms visual analogue scale; VAS = visual analogue scale.  
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Table 6 Known-groups validity 
  
5L p-value§ 3L p-value§ 
Difference 
between 5L 
and 3L 
(mean, SD) 
  
n 
Mean 
(SD) 
Median (IQR)  n 
Mean 
(SD) 
Median (IQR)   
Total sample 204 0.87 (0.12) 0.90(0.80-1.00) - 203 0.80 (0.17) 0.80(0.69-1.00) - 0.07 (0.10)* 
Age groups                   
18-24 37 0.90 (0.10) 0.92 (0.81-1.00) 
0.0357 
37 0.83 (0.16) 0.81 (0.73-1.00) 
0.1230 
0.07 (0.09)* 
25-34 71 0.89 (0.12) 0.92 (0.81-1.00) 71 0.82 (0.17) 0.77 (0.73-1.00) 0.07 (0.10)* 
35-44 58 0.85 (0.12) 0.86 (0.77-0.94) 57 0.77 (0.19) 0.80 (0.69-0.94) 0.08 (0.10)* 
≥45 38 0.84 (0.15) 0.85 (0.79-0.94) 38 0.78 (0.15) 0.74 (0.69-0.88) 0.06 (0.11)* 
Perianal fistulas 
yes 83 0.85 (0.13) 0.86 (0.78-0.94) 
0.0889 
81 0.78 (0.18) 0.80 (0.69-1.00) 
0.2148 
0.07 (0.11)* 
no 121 0.88 (0.12) 0.92 (0.81-1.00) 122 0.81 (0.17) 0.80 (0.69-1.00) 0.07 (0.09)* 
Extraintestinal manifestations 
yes 57 0.81 (0.10) 0.80 (0.74-0.87) 
<0.0001 
54 0.71 (0.14) 0.71 (0.68-0.80) 
<0.0001 
0.10 (0.09)* 
no 147 0.90 (0.12) 0.94 (0.83-1.00) 149 0.83 (0.17) 0.85 (0.73-1.00) 0.06 (0.10)* 
Permanent stoma 
yes 10 0.80 (0.14) 0.78 (0.69-0.93) 
0.0737 
10 0.75 (0.21) 0.69 (0.67-1.00) 
0.2550 
0.06 (0.16) 
no 194 0.87 (0.12) 0.92 (0.81-1.00) 193 0.80 (0.17) 0.80 (0.69-1.00) 0.07 (0.09)* 
Disabled due to CD 
yes 46 0.78 (0.12) 0.80 (0.74-0.86) 
<0.0001 
46 0.68 (0.14) 0.70 (0.61-0.76) 
<0.0001 
0.10 (0.11)* 
no 158 0.90 (0.11) 0.94 (0.83-1.00) 157 0.84 (0.16) 0.85 (0.73-1.00) 0.06 (0.09)* 
Severity groups               
Symptomatic remission (CDAI<150) 154 0.88 (0.11 0.92 (0.81-1.00) 
0.1133 
154 0.82 (0.15) 0.80 (0.69-1.00) 
0.0651 
0.06 (0.09)* 
Mild (CDAI 150-219) 32 0.86 (0.14) 0.90 (0.79-0.99) 31 0.77 (0.21) 0.80 (0.69-1.00) 0.10 (0.10)* 
Moderate-to-severe (CDAI 220≤) 18 0.79 (0.19) 0.80 (0.73-0.94) 18 0.70 (0.23) 0.71 (0.65-0.86) 0.09 (0.15)* 
Perianal fistula severity groups               
Inactive (PDAI≤4) 52 0.86 (0.15) 0.87 (0.79-1.00) 0.2166 51 0.79 (0.19) 0.80 (0.69-1.00) 0.4171 0.06 (0.12)* 
Active (PDAI>4) 30 0.85 (0.10) 0.85 (0.77-0.94) 29 0.76 (0.16) 0.76 (0.69-0.85) 0.09 (0.10)* 
§ Mann-Whitney U test or Kruskal Wallis H test, where a p<0.05 was considered statistically significant. * Wilcoxon signed-rank test, where a p<0.05 was considered 
statistically significant. 
CDAI = Crohn's Disease Activity Index; PDAI = Perianal disease Activity Index  
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Figure legends 
Fig. 1 Distribution of EQ-5D index scores from patients with Crohn’s disease 
 
The UK value set was applied on 3L [38] and the English on 5L data [39].  
 
Fig. 2 Bland-Altman plot of the EQ-5D-3L and EQ-5D-5L index scores in Crohn’s 
disease 
 
The horizontal line represents the mean of the differences (d) between 3L and 5L index 
scores, while the 95% limits of agreement, obtained as d ± 1.96 * SD of d, are indicated by 
dashed lines.  
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